Skip to main navigation Skip to search Skip to main content

Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases

  • Dinesh Kumar Chellappan
  • , Kavita Pabreja
  • , Md Faiyazuddin
  • International Medical University
  • Bioproperties Pty Ltd
  • Al-Karim University

Research output: Book/ReportBookpeer-review

8 Scopus citations

Abstract

This book describes the growing clinical and healthcare relevance of nano-therapeutics in treating respiratory diseases. It begins with a brief introduction on the different types of nanoparticles in respiratory disease conditions. It further discusses the current trends in understanding the disease pathology using different in vitro and in vivo models, which are important towards the onsite clinical applications and development of new therapeutics. The book includes exciting topics such as formulation of these nanoparticles, targeting various organelles etc. It also describes the future prospects and challenges in the field. Different chapters are written by researchers actively working in the area of pulmonary diseases. This book is designed to address the requirements of both beginners and specialized scientists involved in pulmonary research. The contents include basic concepts followed by advanced state-of-art monitoring and treatment of diseases. The book is meant for researchers and industry experts in nanotechnology, pharmaceutical sciences and drug design.

Original languageEnglish
PublisherSpringer Nature
Number of pages655
ISBN (Electronic)9789811643927
ISBN (Print)9789811643910
DOIs
StatePublished - 1 Jan 2022
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Biomarkers
  • Drug Delivery systems
  • Inflammation
  • Nanoparticles
  • Oxidative stress
  • Respiratory diseases

Fingerprint

Dive into the research topics of 'Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases'. Together they form a unique fingerprint.

Cite this